CLS Holdings USA, Inc. Stocks

$ 0.04Last Updated 28.08.2025

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 5.94M

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.04
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

CLS Holdings USA, Inc., a diversified cannabis company, focuses on the extraction and conversion of cannabinoids in the United States. It extracts cannabinoids from the cannabis plants and converts into concentrates, such as oils, waxes, edibles, and shatters. The company sells organic medical cannabis to licensed retailers; recreational marijuana cannabis products to licensed distributors and retailers; extraction products, such as oils and waxes derived from in-house cannabis production; processing and extraction services for licensed medical cannabis cultivators; and cannabis strains in the form of vegetative cuttings to licensed medical cannabis cultivators. It also offers consulting services to cannabis-related businesses comprising growers, dispensaries, and laboratories; and toll processing services. The company provides its products under Oasis Cannabis and City Trees brand names. Its concentrates are used for pharmaceutical and other purposes. The company was founded in 2014 and is based in Miami, Florida.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, undervalued on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks